Anne Van Abbema
About Anne Van Abbema
Anne Van Abbema is a Senior Scientist with extensive experience in drug development and assay development, currently working at Arcus Biosciences. She has over twenty years of experience in both antibody and small molecule drug development, having held various positions at notable companies in the biotechnology sector.
Work at Arcus Biosciences
Anne Van Abbema has been employed at Arcus Biosciences as a Senior Scientist since 2021. In this role, she contributes to the development of innovative therapies, leveraging her extensive background in drug development and assay techniques. Her current work focuses on advancing the company's research initiatives in oncology.
Previous Experience in Biopharmaceuticals
Prior to her role at Arcus Biosciences, Anne Van Abbema held several positions in the biopharmaceutical sector. She served as a Senior Technical Leader at Novartis Institutes for BioMedical Research from 2012 to 2014. Before that, she worked as a Staff Development Scientist at Bayer from 2014 to 2016, and as a Senior Research Associate at Genentech from 2008 to 2012. Her career also includes roles at companies such as Abgenix, PDL BioPharma, Chiron Corp, and Eli Lilly.
Education and Expertise
Anne Van Abbema earned her Bachelor of Arts in Physiology from Southern Illinois University, Carbondale, where she studied from 1985 to 1989. She furthered her education at Indiana University Indianapolis, obtaining a Master of Science in Physiology and Biophysics from 1990 to 1993. Her expertise encompasses both antibody and small molecule drug development, with a focus on high throughput screening and robotic automation of assays.
Career Achievements
With over twenty years of experience in assay development, Anne Van Abbema has a strong history of project progression in the biopharmaceutical industry. She has been recognized with achievement awards for her significant contributions to various projects throughout her career. Her work has consistently advanced the understanding and development of therapeutic solutions.